Chronic cough, defined as a cough persisting over eight weeks, is a challenging condition to diagnose and manage. It not only impacts the patient's quality of life but also poses a diagnostic dilemma for clinicians due to its multifactorial etiology.
A systematic and comprehensive approach is paramount for the successful diagnosis of chronic cough. The initial evaluation should include a detailed history and physical examination to identify common causes such as upper airway cough syndrome, gastroesophageal reflux disease (GERD), and asthma. If the cough persists despite initial therapy, further investigations such as chest radiographs, spirometry, and bronchoprovocation tests may be warranted.
Imaging studies, particularly high-resolution computed tomography (HRCT), can reveal underlying pulmonary disorders. Laboratory tests, including complete blood count (CBC), can help identify eosinophilic bronchitis. In refractory cases, bronchoscopy may be necessary to evaluate for conditions like endobronchial tumors or foreign bodies.
Management of chronic cough should be tailored to the underlying cause. Empiric treatment for the most common causes such as GERD, asthma, and postnasal drip syndrome can be initiated. In refractory cases, a multidisciplinary approach involving pulmonologists, gastroenterologists, and otolaryngologists may be required.
Recent advancements in the understanding of chronic cough pathophysiology have led to the development of promising therapies. Neuromodulators such as gabapentin and pregabalin have shown efficacy in refractory chronic cough. Moreover, novel therapies targeting neuronal pathways, such as P2X3 receptor antagonists, are currently under investigation.
In conclusion, chronic cough remains a complex clinical entity requiring a comprehensive and systematic approach for effective diagnosis and management. Embracing a multidisciplinary approach, utilizing advanced diagnostic tools, and keeping abreast of emerging therapies can significantly improve patient outcomes.
1.
A three-quarters reduction in the risk of prostate cancer is associated with an annual increase in cardiorespiratory fitness of more than three percent.
2.
Study Homes In on Simpler Lung Cancer Screening Criteria
3.
Novel analysis identifies markers that may predict failure of metastatic prostate cancer treatment
4.
No Survival Bump in Metastatic NSCLC With Addition of ADC to Immunotherapy
5.
More Positive Survival Data in Lung Cancer With Perioperative Therapy
1.
Bone Marrow Microenvironment Biomarkers in Hematologic Health
2.
Emerging Insights in Hematology for Better Care
3.
Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors
4.
Radioligand Therapy Advances: PSMA, Neuroendocrine, and Solid Tumor Clinical Insights
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
International Conference on Oncology, Cardiology and Critical Care Policy
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Cancer Nursing and Hematology Support
1.
Expert Perspectives on Hematology
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI
3.
How Multidisciplinary Teams Support Modern Cancer Care
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV
5.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation